Fitusiran in Hemophilia: A Novel Therapeutic Approach Targeting Antithrombin

By Anna Dalton, PharmD, Ryan Clark, PharmD, Justin R. Arnall, PharmD, BCOP, FCCP, P. Christopher Parish, PharmD, BCOP, Lyndsi Roland, PharmD, MSCR

This article contains an overview of hemophilia and current treatment and prophylactic strategies, highlighting the key differences between fitusiran and other agents used for prophylaxis.

Recombinant ADAMTS13: An Enzyme Replacement Therapy for the Management of Congenital Thrombotic Thrombocytopenic Purpura

By Taylor P. Robichaux, PharmD, BCPS, CACP, Kathryn E. Dane, PharmD, BCPS, P. Christopher Parish, PharmD, BCOP, Justin R. Arnall, PharmD, BCOP, FCCP, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP

Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare autosomal recessive condition that causes deficiency of the von Willebrand factor (vWF)-cleaving metalloprotease, ADAMTS13. Recombinant ADAMTS13 (rADAMTS13) is the first FD...

Can a Benign Hematology Phenomenon Critically Impact the Neutropenia Status and Treatment of Patients With Cancer?

By Amandine P. Ndje, MS, MBA, APRN, FNP-C

Neutropenia in oncology care usually has a disease-related or therapy-related etiology. However, for a population with a benign hematology phenomenon known as benign ethnic neutropenia (BEN) or Duffy-null associated neutrophil count (DAN...

ASH Highlights and Commentary: Blood Disorders

By Brad Lewis, MD

Brad Lewis, MD, of Machaon Diagnostics, reviews three studies on acquired hemophilia, thrombotic thrombocytopenic purpura, and hereditary hemorrhagic telangiectasia.